Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'

Jim Cramer, on 'Mad Money,' expressed strong skepticism regarding several companies, advising against Tempus AI due to significant losses and labeling Insmed and Ouster as overly speculative, with Ouster also facing an analyst downgrade. Despite Cramer's profitability-focused stance, First Majestic Silver, Ouster, and Insmed all saw share price gains following company-specific news, including positive study results for Insmed and an outlook raise for First Majestic, highlighting a divergence between his commentary and immediate market reactions, while Tempus AI experienced a minor decline.

Analysis

The provided commentary highlights a significant divergence between a fundamentals-first investment philosophy, articulated by Jim Cramer, and the market's reaction to company-specific catalysts. Cramer's negative stance on Tempus AI (TEM), Insmed (INSM), and Ouster (OUST) is rooted in their current unprofitability, labeling them as overly speculative and citing substantial financial losses. This perspective, however, is contrasted by recent positive developments that the market appears to be rewarding. Specifically, Insmed announced its Phase 2b study met its primary and secondary endpoints, and First Majestic Silver (AG) raised its full-year 2025 production outlook, leading to share price gains of 0.3% and 5.5% respectively. Even Ouster, which faced both Cramer's criticism and an analyst downgrade to Hold, saw its shares climb 6.4%. This price action suggests that investors are currently prioritizing forward-looking catalysts—such as clinical trial success, strategic partnerships like Tempus AI's with Personalis, and improved production guidance—over the immediate lack of profitability that forms the basis of Cramer's cautionary advice.

Key Decisions for Investors

• Investors should weigh company-specific catalysts, such as Insmed's positive Phase 2b trial results and First Majestic's raised guidance, against broader media commentary focused on historical profitability.
• For speculative technology and biotech names like Ouster and Insmed, consider that the market may be pricing in future growth potential from operational milestones, despite current cash burn and analyst concerns.
• When evaluating Tempus AI, it is critical to balance the significant reported losses against tangible business development, like the expanded collaboration with Personalis, to assess its long-term viability.
• In the commodities sector, consider that forward-looking operational updates, which drove First Majestic Silver's 5.5% gain, can be a more immediate share price driver than a peer's history of profitability.